Alprostadil (Caverject/MUSE) Bone Health and Density Impact

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1), approved by the FDA for the management of erectile dysfunction both as an intracavernosal injection (Caverject, 2.5 to 40 mcg per dose) and as an intraurethral suppository (MUSE, 125 to 1,000 mcg per dose). The drug binds adenylyl cyclase-coupled prostaglandin receptors, raising intracellular cyclic AMP in smooth muscle cells of the corpus cavernosum and triggering vasodilation and penile tumescence. Linet et al. Demonstrated approximately 70% response rates in men with refractory ED who had already failed PDE5 inhibitor therapy.

Receptor Pharmacology Relevant to Bone

The prostaglandin E receptor family comprises four subtypes: EP1, EP2, EP3, and EP4. Bone cells express all four, but EP2 and EP4 receptors are particularly dense on osteoblast precursors and are the principal mediators of PGE1/PGE2-stimulated bone formation. EP2 signals primarily through Gs-protein/cAMP pathways; EP4 couples to both Gs and PI3K/Akt, giving it a broader anabolic profile. When systemic PGE1 levels rise, even transiently, these receptors are activated.

Systemic Absorption After Local Delivery

A common assumption is that intracavernosal injection confines drug action to penile tissue. Pharmacokinetic data published in the British Journal of Clinical Pharmacology show detectable plasma PGE1 within minutes of Caverject injection, though rapid pulmonary metabolism limits peak plasma concentrations. MUSE (intraurethral alprostadil) produces somewhat higher transient systemic levels because urethral absorption bypasses the first cavernosal pass. Neither route produces sustained plasma concentrations comparable to intravenous PGE1, but repeated dosing over months to years cumulatively stimulates bone receptors in ways that have not been fully characterized in long-term prospective studies.

Prostaglandin E1 and Bone Remodeling: The Basic Science

Bone is a metabolically active tissue that undergoes continuous remodeling. Osteoblasts form new matrix; osteoclasts resorb it. Prostaglandins sit at the intersection of both processes, acting as local autocrine and paracrine signals within bone microenvironments.

Anabolic Effects on Osteoblasts

Animal studies using systemic PGE2 administration have documented trabecular bone volume increases of 6 to 10% in rodent models over 4 to 8 week periods, primarily through EP4-mediated stimulation of Wnt/beta-catenin signaling in osteoblast progenitors. PGE1 shares sufficient structural similarity with PGE2 to activate EP2 and EP4 with comparable affinity, suggesting a parallel anabolic potential. Ep4-knockout mouse models confirm that removing this receptor blunts bone formation responses to mechanical loading and PGE treatment, which reinforces its mechanistic centrality.

Resorptive Effects via Osteoclast Activation

PGE1 does not act purely as a bone builder. At higher concentrations, prostaglandins stimulate RANKL expression on osteoblasts, which in turn recruits and activates osteoclast precursors. Preclinical data from Sakuma et al. Show dose-dependent biphasic effects: low-concentration PGE2 favors bone formation while high concentrations shift the balance toward resorption. The clinical relevance for alprostadil users is uncertain, but men receiving higher MUSE doses (750 to 1,000 mcg) multiple times weekly may experience net effects that differ from those using lower intracavernosal doses twice monthly.

Prostaglandins and Bone-Remodeling Markers

Serum markers of bone turnover, including C-terminal telopeptide (CTX) for resorption and procollagen type I N-terminal propeptide (P1NP) for formation, respond to prostaglandin signaling shifts. No published randomized controlled trial has prospectively measured CTX or P1NP before and after chronic alprostadil therapy. This gap in the literature is one reason clinicians often overlook bone monitoring in their ED treatment protocols.

The ED-Hypogonadism-Bone Triangle

Erectile dysfunction does not occur in a metabolic vacuum. Men presenting with refractory ED, the population most likely to receive alprostadil, carry a substantially elevated prevalence of hypogonadism, metabolic syndrome, and type 2 diabetes, all of which independently compromise bone density.

Hypogonadism as the Primary Confound

Testosterone deficiency is documented in 20 to 40% of men with organic erectile dysfunction depending on the diagnostic cutoff used. Testosterone exerts direct anabolic effects on bone by inhibiting osteoclast apoptosis and stimulating osteoblast proliferation. The Endocrine Society's 2018 Testosterone Therapy guideline specifies that men with hypogonadism should be screened with dual-energy X-ray absorptiometry (DXA) regardless of age, precisely because low testosterone is an established secondary cause of osteoporosis in men.

Men who require alprostadil after failing sildenafil, tadalafil, or vardenafil should have total testosterone, free testosterone, LH, and FSH measured before initiating long-term therapy. If testosterone is below 300 ng/dL by two morning measurements, the American Urological Association's 2018 guideline on male hypogonadism supports initiating testosterone replacement therapy, which would both address the hormonal deficiency and benefit bone independently of alprostadil.

Metabolic Syndrome, Type 2 Diabetes, and Bone Quality

Metabolic syndrome affects a significant portion of men with ED. A meta-analysis by Corona et al. (J Sex Med, 2011) found that metabolic syndrome was present in approximately 42% of men referred for ED evaluation. Insulin resistance and chronic low-grade inflammation alter bone quality through advanced glycation end-products (AGEs) that stiffen collagen cross-links, reducing fracture resistance even when DXA T-scores appear preserved. The American Diabetes Association's Standards of Care note that type 2 diabetes paradoxically raises fracture risk despite normal or elevated bone mineral density, underscoring that DXA alone may underestimate skeletal fragility in diabetic men.

Vascular Disease as a Shared Pathway

Alprostadil is most commonly prescribed in men with vasculogenic ED, driven by endothelial dysfunction and reduced nitric oxide bioavailability. Atherosclerosis and bone loss share overlapping pathophysiology through oxidized LDL-driven osteoblast inhibition and vascular calcification. Men with severe vasculogenic ED requiring alprostadil may therefore already have compromised bone metabolism before the first injection is administered.

Evidence From Clinical Studies: What We Know and What We Don't

No randomized controlled trial has been designed with bone density as a primary endpoint for alprostadil. The evidence base is assembled from mechanistic studies, pharmacokinetic data, observational cohorts in adjacent populations, and extrapolation from intravenous PGE1 use in other conditions.

Intravenous PGE1 Data From Neonatal and Vascular Studies

Intravenous alprostadil has been used for decades in neonates with congenital heart disease and in adults with critical limb ischemia. Long-term intravenous PGE1 in pediatric cardiac patients has been associated with cortical hyperostosis, a pathological excess of bone formation, at doses of 0.05 to 0.1 mcg/kg/min for more than 4 weeks. This side effect confirms that systemic PGE1 is biologically active in bone at sustained plasma concentrations. The doses used intravenously far exceed what reaches systemic circulation after local ED therapy, but the mechanism is the same.

Observational Data in Men With ED

A Danish registry study by Fode et al. Examining men treated for ED found that those with organic etiology had significantly lower bone mineral density than age-matched controls without ED, independent of testosterone levels. The study did not stratify by treatment modality, so alprostadil-specific effects cannot be extracted. The finding does confirm that the population receiving alprostadil carries baseline skeletal risk.

The Prostaglandin Analogue Precedent

Misoprostol, a PGE1 analogue, and bimatoprost, a prostaglandin F2alpha analogue, have both been studied in bone contexts. Bimatoprost (0.03% ophthalmic solution) increased periorbital bone resorption in long-term glaucoma patients, demonstrating clinically measurable skeletal effects from topical prostaglandin analogues. This precedent supports the principle that exogenous prostaglandins can alter bone metabolism at tissue concentrations lower than traditionally assumed.

What the Linet Trial Did Not Measure

The landmark Linet et al. NEJM 1996 trial enrolled 296 men with chronic organic ED and demonstrated that intracavernosal alprostadil produced clinically meaningful erections suitable for intercourse in approximately 70% of injections, compared with 16% for placebo. The trial followed patients for 6 months. Bone density, bone turnover markers, and testosterone levels were not measured. Safety data captured pain at injection site, prolonged erection, and hypotension, but not skeletal endpoints. Six months is also insufficient to capture DXA-detectable changes, which typically require 12 to 24 months.

Alprostadil Formulations: Caverject vs. MUSE and Skeletal Implications

The two FDA-approved alprostadil formulations differ in dose range, absorption kinetics, and likely systemic exposure, all of which matter when assessing cumulative bone receptor stimulation.

Caverject (Intracavernosal Injection)

Caverject is available in 5, 10, 20, and 40 mcg vials. The effective dose for most men ranges from 5 to 20 mcg per injection. Pulmonary first-pass metabolism clears approximately 80% of absorbed PGE1 in a single pass, substantially limiting systemic bioavailability. Men using Caverject 2 to 3 times weekly at 20 mcg accumulate far less systemic PGE1 exposure than patients receiving intravenous infusions for vascular indications.

MUSE (Intraurethral Suppository)

MUSE delivers 125, 250, 500, or 1,000 mcg of alprostadil directly to urethral mucosa, which then diffuses to the corpus cavernosum via periurethral venous plexuses. Systemic absorption is variable. Padma-Nathan et al. Documented that MUSE produced adequate erections in 65% of men in a randomized placebo-controlled trial, with a notable incidence of penile pain (32%) and urethral burning. Higher urethral doses mean higher potential systemic exposure compared with equivalent therapeutic intracavernosal doses.

Dose-Frequency Calculus for Bone Risk

A man using MUSE 500 mcg daily for sexual activity compared with a man using Caverject 10 mcg twice monthly represents a cumulative PGE1 load difference of roughly 30-fold over a year. Whether this gap translates to measurable bone density differences has not been studied. Based on the dose-response principles established in preclinical prostaglandin receptor pharmacology, the higher-dose, higher-frequency MUSE user warrants closer bone metabolic monitoring.

Practical Clinical Framework: Bone Monitoring in Alprostadil Users

Prescribing clinicians should integrate bone health assessment into alprostadil management rather than treating ED therapy and skeletal health as separate domains. The following framework reflects existing guideline recommendations applied to this specific patient population.

Step 1: Baseline Hormonal and Metabolic Assessment

Before initiating or continuing alprostadil therapy, obtain:

• Total testosterone and free testosterone (two morning samples, <10 AM)
• LH and FSH to distinguish primary from secondary hypogonadism
• Fasting glucose and HbA1c to screen for metabolic syndrome and diabetes
• 25-hydroxyvitamin D (target 30 to 50 ng/mL per Endocrine Society guidelines)
• Serum calcium and parathyroid hormone if vitamin D is deficient

Step 2: DXA Scanning Criteria

DXA is warranted in alprostadil users who meet any of the following:

• Total testosterone below 300 ng/dL on two measurements
• Age 50 or older with additional osteoporosis risk factors (smoking, corticosteroid use, family history of hip fracture)
• Type 2 diabetes with duration exceeding 10 years
• Body mass index <20 kg/m2

The National Osteoporosis Foundation recommends DXA in men age 70 or older universally, and in men age 50 to 69 with risk factors. Men presenting with refractory ED in their 50s and 60s often carry enough compounding risk to justify earlier scanning.

Step 3: FRAX Score Calculation

The WHO Fracture Risk Assessment Tool (FRAX) estimates 10-year probability of major osteoporotic fracture and hip fracture. Men with a FRAX-estimated 10-year hip fracture risk exceeding 3% or major osteoporotic fracture risk exceeding 20% meet the National Osteoporosis Foundation threshold for pharmacological intervention with bisphosphonates or other anti-resorptive agents, independent of their alprostadil use.

Step 4: Testosterone Replacement as a Bone-Protective Co-Intervention

Men with confirmed hypogonadism who are using alprostadil for ED represent a population where testosterone replacement therapy (TRT) may serve dual purposes: improving sexual function enough to reduce alprostadil dose frequency, and directly rebuilding bone density. The TRAVERSE trial (N=5,246) demonstrated that testosterone replacement in hypogonadal men with cardiovascular risk did not increase major adverse cardiovascular events and produced modest improvements in bone-related quality of life measures. TRT should be co-managed with bone density monitoring at 12 to 24 month intervals.

Step 5: Vitamin D and Calcium Optimization

Regardless of alprostadil use, men with ED-associated risk factors should achieve vitamin D sufficiency. A 2022 meta-analysis in the BMJ (N=81,512 across 46 trials) found that vitamin D supplementation reduced cancer mortality by 12% but did not significantly reduce fracture rates in unselected populations. The fracture benefit appears stronger in vitamin D-deficient men with baseline 25-OH-D below 20 ng/mL. Calcium intake should reach 1,000 to 1,200 mg/day through dietary sources first, with supplementation only when diet falls short, per National Institutes of Health Office of Dietary Supplements recommendations.

Drug Interactions Relevant to Bone Health in Alprostadil Users

Men receiving alprostadil often take multiple cardiovascular medications. Several interact with bone metabolism.

Antihypertensives

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) reduce urinary calcium excretion and may modestly protect bone density, a benefit in men with co-existing hypertension. Loop diuretics (furosemide) have the opposite effect, increasing calciuria and accelerating bone loss. Alprostadil's vasodilatory action can potentiate antihypertensive effects, so dose adjustments at initiation may shift the patient's diuretic regimen, inadvertently altering calcium balance.

Phosphodiesterase Type 5 Inhibitors Used Intermittently

Some men use alprostadil as a rescue agent on days when sildenafil or tadalafil fail, rather than as exclusive therapy. Emerging in vitro data suggest PDE5 inhibitors may have modest pro-osteoblastic effects through cGMP signaling pathways, though clinical evidence in men is preliminary. Concurrent use does not raise a documented safety concern for bone, but the possible additive or antagonistic interaction at the level of cyclic nucleotide signaling in osteoblasts has not been characterized in human trials.

Corticosteroids

Men with inflammatory or autoimmune conditions sometimes use chronic corticosteroids. Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis, with fracture risk increasing by 30 to 50% within the first 3 to 6 months of prednisone use at doses above 5 mg/day. An alprostadil user on chronic prednisone warrants DXA at baseline and initiation of bisphosphonate therapy per American College of Rheumatology 2022 guideline rather than watchful waiting.

Monitoring Schedule and Clinical Decision Points

Systematic follow-up for alprostadil users with identified bone risk should follow a structured timeline.

At Alprostadil Initiation

• Complete hormonal panel (testosterone, LH, FSH, SHBG)
• Metabolic panel including fasting glucose, HbA1c, lipids
• 25-hydroxyvitamin D, calcium, PTH
• DXA if any of the criteria above are met
• FRAX score documentation in the medical record

At 6 Months

• Assess alprostadil dose and frequency (Caverject vs. MUSE, doses used)
• Repeat testosterone if baseline was borderline (280 to 320 ng/dL range)
• Review vitamin D repletion response with repeat 25-OH-D level

At 12 to 24 Months

• Repeat DXA if baseline T-score was below -1.0 (osteopenia range)
• Reassess FRAX score incorporating any interval fracture events
• Measure CTX and P1NP bone turnover markers if DXA change exceeds measurement error (typically 3 to 5% at spine, 4 to 6% at hip depending on the DXA system's precision)
• Evaluate whether testosterone optimization has reduced the need for alprostadil dose frequency

The Endocrine Society's 2012 clinical practice guideline on osteoporosis in men recommends repeat DXA at 1 to 2 year intervals for men with osteopenia on treatment and at 2-year intervals for those on stable, optimized therapy.

Safety Profile of Alprostadil: What the Trials Show

Alprostadil's established adverse effects center on local reactions and hemodynamic changes. Bone-specific adverse events have not been reported in ED trials, likely because trials were not designed or powered to detect them and follow-up durations were insufficient.

Established Adverse Events From the Linet Trial and Post-Marketing Data

The Linet NEJM 1996 trial reported penile pain in up to 37% of Caverject users, prolonged erection (priapism) in 4%, and hypotension in 3.3%. FDA-approved prescribing information for Caverject lists fibrosis, Peyronie's disease with repeated injection, and systemic hypotension as the most clinically significant safety concerns. Bone-related adverse events appear in neither the trial data nor the prescribing label, which reflects the absence of dedicated skeletal study rather than confirmed skeletal safety.

The Pediatric Cortical Hyperostosis Signal

The periosteal cortical bone overgrowth observed in neonates receiving long-term intravenous PGE1 for ductal-dependent congenital heart disease at doses of 0.05 to 0.1 mcg/kg/min was reversible upon drug discontinuation. This finding does not predict the same outcome in adult men using low-dose local therapy, but it establishes biological plausibility for skeletal PGE1 effects and was serious enough to be included in neonatal drug safety summaries.